SORT1 and thyroid cancer: In melanoma [16], breast [33] and thyroid cancer [34], proNGF blocking antibodies have been reported to have no impact on cancer cell growth but instead targeting proNGF led to a decreased cancer migration and invasion through a mechanism involving p75NTR and sortilin [16].